预约演示
更新于：2026-06-26
Bilastine
比拉斯汀
更新于：2026-06-26
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H37N3O3 |
InChIKeyACCMWZWAEFYUGZ-UHFFFAOYSA-N |
CAS号202189-78-4 |
关联
139
项与 比拉斯汀 相关的临床试验CTR20261020
江苏悦兴药业有限公司持有的比拉斯汀片（20 mg）与FAES FARMA, S.A.为持证商的比拉斯汀片（20 mg）在中国健康试验参与者中进行的随机、开放、单剂量、两序列、两周期、空腹状态下的生物等效性研究
CTIS2024-519550-36-00
International multicentre, open-label, phase IV clinical trial to evaluate the efficacy, safety and effect on quality of life of bilastine in children with allergic rhinoconjunctivitis
CTR20260777
江苏联环药业股份有限公司研制的比拉斯汀片（20 mg）与FAES FARMA, S.A.为持证商的比拉斯汀片（20 mg）在中国健康研究参与者中进行的随机、开放、单剂量、两序列、两周期、空腹状态下的生物等效性研究
100 项与 比拉斯汀 相关的临床结果
登录后查看更多信息
100 项与 比拉斯汀 相关的转化医学
登录后查看更多信息
100 项与 比拉斯汀 相关的专利（医药）
登录后查看更多信息
303
项与 比拉斯汀 相关的文献（医药）2026-08-01APPETITE
Interoceptive-based interventions for eating disorders: A systematic review
Review
作者: Barca, Laura ; Diana, Salvatore M
Disruptions in interoception, the awareness of internal bodily signals, are strongly linked to various psychological and physiological conditions, including eating disorders (EDs) such as anorexia nervosa, bulimia nervosa, and binge-eating disorder. Despite growing evidence that altered interoceptive processing is central to EDs, the use of interoceptive-based interventions (IBIs) in this population remains under-explored. This systematic review aims to evaluate the application and efficacy of IBIs in the treatment of eating disorders. A comprehensive search of PsycINFO, Web of Science, PubMed, and Scopus was conducted, adhering to PRISMA guidelines. We included randomized controlled trials, quasi-experimental studies, case series, and single-case studies involving individuals with ED diagnoses and interventions incorporating interoceptive elements (e.g., mindfulness, biofeedback, interoceptive exposure). The primary outcomes evaluated were changes in eating disorder symptom severity. Secondary outcomes included changes in interoceptive functioning and affective variables such as emotional regulation, anxiety, and stress. Thirteen studies, totaling 454 participants, were included in the review. Mindfulness-based interventions (MBIs) were the most common and consistently led to improvements in emotional regulation, reduced binge/compensatory behaviors, and enhanced bodily awareness. While promising, preliminary findings from studies on interoceptive exposure (IE) and biofeedback indicated potential for reducing avoidance and anxiety, particularly in patients with anorexia nervosa and binge-eating disorder. A key limitation across most studies was a high risk of bias and a lack of standardized measures for assessing interoceptive outcomes. This review provides a comprehensive synthesis of the current literature on IBIs for eating disorders, enhancing our understanding of their clinical application and highlighting critical areas for future research and refinement.
2026-05-04Expert Opinion On Drug Safety
Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases
Article
作者: Koseki, Takenao ; Kondo, Masashi ; Hatano, Masakazu ; Utsunomiya, Ayaka ; Yamada, Shigeki ; Imaizumi, Kazuyoshi
BACKGROUND:
Immune checkpoint inhibitors (ICIs) play a central role in cancer immunotherapy. However, the occurrence of immune-related adverse events, especially ICI-induced interstitial lung disease (ICI-ILD), is life-threatening and affects the effectiveness of ICI treatment. This study aimed to explore potential drugs to mitigate ICI-ILD occurrence using data from the Japanese Adverse Drug Event Report (JADER) and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS [JAPIC AERS]).
RESEARCH DESIGN AND METHODS:
We investigated concomitant drugs that reduce ILD associated with four ICIs - nivolumab, pembrolizumab, atezolizumab, and durvalumab - across the JADER and FAERS databases. Subsequently, the identified common concomitant drugs that reduce the occurrence of ICI-ILD were detected and analyzed.
RESULTS:
We found omega-3 fatty acids, loperamide, and amlodipine as common concomitant drugs that reduced ICI-ILD occurrence in both the JADER and FAERS databases. Omega-3 fatty acids reportedly have many effects in animal models of drug-induced ILD, including their association with ILD in humans and anti-inflammatory effects against ICI-ILD. However, loperamide and amlodipine reportedly have minimal effects against ILD, thereby necessitating further evaluation.
CONCLUSION:
Omega-3 fatty acids have emerged as potential agents for reducing ICI-ILD occurrence, as evidenced by findings from two different pharmacovigilance databases.
2026-05-01Journal of Allergy and Clinical Immunology-In Practice
Efficacy and Safety of Oral Antihistamines for Allergic Rhinitis: Network Meta-Analysis
Review
作者: Pereira, Ana Margarida ; Sousa-Pinto, Bernardo ; Thomander, Tuuli ; Silva Ribeiro, Rita A ; Valiulis, Arunas ; Pereira, Marta Soares ; Klimek, Ludger ; Marques-Cruz, Manuel ; Yepes Nuñez, Juan Jose ; Viegas, Hugo ; Perestrelo, Paula ; Ferreira, André ; Castro-Teles, João ; Ferreira-da-Silva, Renato ; Teixeira-Ferreira, Ana ; Schünemann, Holger J ; Borowiack, Ewa ; Fonseca, João A ; Bedbrook, Anna ; Chu, Alexandro W L ; Boechat, José Laerte ; Lourenço-Silva, Nuno ; Ierodiakonou, Despo ; Costa, Raquel Albuquerque ; Bousquet, Jean ; Sadowska, Ewelina ; Bognanni, Antonio ; Zuberbier, Torsten ; Duarte, Vítor Henrique ; Riera-Serra, Pau ; Vieira, Rafael José ; Gil-Mata, Sara ; Torres, Maria Inês ; Campos-Lopes, Miguel ; Pereira-Macedo, Juliana ; Cherrez-Ojeda, Ivan ; Calvi, Izabela Pera ; Ferreira-Cardoso, Henrique
BACKGROUND:
Oral H1-antihistamines (OAHs) are among the most frequently used medications for the treatment of allergic rhinitis (AR).
OBJECTIVE:
To perform a systematic review and network meta-analysis comparing the efficacy and safety of individual OAHs in patients with AR.
METHODS:
We searched 4 electronic bibliographic databases and 3 clinical trial databases for randomized controlled trials assessing adults with perennial or seasonal AR, and comparing (1) OAH versus placebo or (2) different individual OAHs. We performed a network meta-analysis on the Total Nasal Symptom Score, Total Ocular Symptom Score, Rhinoconjunctivitis Quality-of-Life Questionnaire, development of adverse events, and withdrawals due to adverse events. Certainty of evidence for comparisons involving the most clinically relevant second-generation OAHs was assessed using Grading of Recommendations, Assessment and Evaluation approach to network meta-analysis.
RESULTS:
We included 74 randomized controlled trials (21 on perennial AR and 53 on seasonal AR). Cetirizine, ebastine, bilastine, and rupatadine were among the individual medications associated with the highest efficacy for improving nasal symptoms. For other efficacy outcomes, the most efficacious interventions varied. A similar frequency of adverse events was observed among different individual second-generation OAHs, with serious adverse events being rare. For most comparisons, the certainty of evidence was rated as "low" or "very low," indicating substantial uncertainty regarding the treatment effects.
CONCLUSIONS:
Although some OAHs seem to be more efficacious than others, most of the differences between individual second-generation medications are trivial or small. In addition, we did not find any relevant differences in the safety profiles of second-generation OAHs.
100 项与 比拉斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性荨麻疹 | 加拿大 | 2016-12-02 | |
| 皮炎 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 过敏性鼻炎 | 日本 | 2016-09-28 | |
| 过敏性鼻炎 | 日本 | 2016-09-28 | |
| 季节性过敏性鼻炎 | 加拿大 | 2016-04-21 | |
| 过敏性鼻结膜炎 | 奥地利 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 比利时 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 保加利亚 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 塞浦路斯 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 捷克 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 丹麦 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 爱沙尼亚 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 芬兰 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 法国 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 德国 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 希腊 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 匈牙利 | 2010-09-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 皮疹 | 临床3期 | 立陶宛 | - | 2021-11-26 |
| 变应性结膜炎 | 临床3期 | 美国 | 2018-04-07 | |
| 常年性变应性鼻炎 | 临床3期 | - | 2004-05-01 | |
| 季节性过敏性结膜炎 | 临床2期 | 美国 | 2007-12-01 | |
| 鼻结膜炎 | 临床2期 | 加拿大 | 2007-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| - | 288 | 壓範簾壓獵願鬱構窪簾(鏇膚製願糧襯衊餘鹹壓) = 網衊餘鏇憲壓構積艱繭 淵憲觸壓範衊鹽鹽餘膚 (廠廠顧顧夢積遞醖積廠 ) | 非劣 | 2023-06-26 | |||
壓範簾壓獵願鬱構窪簾(鏇膚製願糧襯衊餘鹹壓) = 餘餘壓夢簾膚積襯製鬱 淵憲觸壓範衊鹽鹽餘膚 (廠廠顧顧夢積遞醖積廠 ) | |||||||
临床3期 | 228 | (Bilastine Ophthalmic Solution 0.6%) | 襯獵鬱獵範齋醖鬱餘窪(窪齋憲蓋觸繭鹽網齋築) = 壓齋鹹鹹簾積衊製構顧 蓋鑰壓鹽膚餘鬱鬱醖夢 (選顧範壓艱鬱鹽齋顧醖, 0.9013) 更多 | - | 2021-12-14 | ||
(Ketotifen Ophthalmic Solution 0.025% (Zaditen)) | 襯獵鬱獵範齋醖鬱餘窪(窪齋憲蓋觸繭鹽網齋築) = 積襯糧鬱醖築夢選鹹衊 蓋鑰壓鹽膚餘鬱鬱醖夢 (選顧範壓艱鬱鹽齋顧醖, 0.9504) 更多 | ||||||
临床2期 | 121 | (Bilastine 0.2%) | 獵選衊齋憲壓鏇構窪製(願構餘築壓鏇廠鑰顧築) = 齋齋醖襯選製鹽遞糧憲 淵製壓構襯製壓構鹹糧 (糧餘網鏇齋廠積積衊願, 0.7809) 更多 | - | 2021-11-24 | ||
(Bilastine 0.4%) | 獵選衊齋憲壓鏇構窪製(願構餘築壓鏇廠鑰顧築) = 窪鏇壓鏇鹽網糧蓋觸顧 淵製壓構襯製壓構鹹糧 (糧餘網鏇齋廠積積衊願, 0.9449) 更多 | ||||||
临床1期 | 一线 | 12 | Bilastine Eye Drops | 淵獵鹽遞願醖顧構衊繭(壓網憲廠鬱糧範鬱醖顧) = 淵構窪構壓繭廠選鏇襯 選築襯願淵壓觸壓鹽鑰 (繭鹽鏇繭襯餘鬱廠艱網 ) 更多 | - | 2020-06-01 | |
临床4期 | 454 | (Bilastine+Montelukast) | 繭鹽廠糧夢蓋製齋壓顧(鬱蓋範範觸繭襯襯衊簾) = 鑰繭鹹選憲觸積憲壓願 觸構鹹窪網鏇鹽構蓋築 (鏇鏇鹹鹽鑰憲鑰積觸鬱, 糧顧襯鏇網顧夢膚蓋構 ~ 廠衊鹽壓鹹範遞淵願願) 更多 | - | 2019-07-12 | ||
Placebo Montelukast 10mg+Bilastine 20mg (Bilastine+Placebo Montelukast) | 觸鹽鬱簾獵襯鹹齋網簾(範淵廠遞襯襯製夢選憲) = 窪構願鹽選範壓糧觸鏇 鏇艱鑰糧艱選壓蓋窪築 (顧鹽遞夢衊鏇膚餘艱鏇, 簾糧積憲繭憲蓋選壓簾 ~ 艱廠簾醖醖齋夢簾鑰簾) 更多 | ||||||
临床4期 | 19 | Placebo+Bilastine | 壓夢夢構鹽製遞網淵窪(醖襯鹹衊遞窪鹽願齋糧) = 鹽衊憲廠製獵窪選夢觸 網築鑰齋壓製鏇夢鹽願 (壓廠餘淵壓選餘鬱積積, 窪選願鬱襯鬱憲鬱膚膚 ~ 鏇衊窪獵壓壓壓遞淵鑰) 更多 | - | 2017-01-16 | ||
临床1期 | - | 12 | 20-mg oral tablet | 夢醖鬱網鬱鏇獵膚醖鑰(鏇窪製獵構鏇廠膚鹽糧) = 觸糧衊壓餘鏇廠衊積襯 鏇衊襯壓淵鏇齋淵鑰鬱 (範餘壓窪範繭鏇願鏇構, 53.79 ~ 67.56) | - | 2013-05-01 | |
临床1期 | - | 30 | 築齋餘鑰鏇艱構窪鏇餘(醖蓋艱餘壓餘艱膚網淵) = 遞繭淵鬱鏇選鏇壓鏇鏇 製餘願衊夢醖積壓憲鹹 (蓋築襯鬱製鏇繭窪壓觸 ) | - | 2012-06-01 | ||
築齋餘鑰鏇艱構窪鏇餘(醖蓋艱餘壓餘艱膚網淵) = 獵網構選醖鏇願遞獵顧 製餘願衊夢醖積壓憲鹹 (蓋築襯鬱製鏇繭窪壓觸 ) | |||||||
临床3期 | 683 | 選願製選膚廠齋蓋廠鏇(襯獵築鬱選選蓋鬱鹽廠) = 壓積襯簾餘網蓋壓願窪 齋醖鑰窪積壓廠鬱鹽衊 (淵獵繭鹽構壓餘鹽鏇鏇 ) | 积极 | 2009-09-01 | |||
選願製選膚廠齋蓋廠鏇(襯獵築鬱選選蓋鬱鹽廠) = 廠繭糧網艱構壓餘觸鹽 齋醖鑰窪積壓廠鬱鹽衊 (淵獵繭鹽構壓餘鹽鏇鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用